Table 4.
Effect of Pam3CSK4 (TLR2), Poly(IC)LC (TLR3), MPLA (TLR4), Imiquimod (TLR7), R848 (TLR7/8) and CpG (TLR9) with rF1V vaccine on F1 and V antibody response in BALB/c mice.
| Vaccine Treatmentc | IgG Titera b | |
|---|---|---|
| Anti-F1 | Anti-V | |
| PBS | 50 (1) | 50 (1) |
| CpG 2006 (25 μg) | 50 (1) | 50 (1) |
| MPLA (25 μg) | 50 (1) | 50 (1) |
| Imiquimod (25 μg) | 50 (1) | 50 (1) |
| Pam3CSK4 (25 μg) | 57 (1.14) | 50 (1) |
| Poly (IC)LC (25 μg) | 57 (1.14) | 50 (1) |
| R848 (25 μg) | 50 (1) | 50 (1) |
| rF1V (0.5 μg) | 96,858 (1.32) | 416,801 (1.34) |
| rF1V (0.5 μg) + CpG2006 (5 μg) | 188,638 (1.27) | 1,355,862 (1.41)* |
| rF1V (0.5 μg) + CpG2006 (25 μg) | 552,067 (1.35)*** | 1,735,651 (1.26)*** |
| rF1V (0.5 μg) + MPLA (5 μg) | 167,692 (1.3) | 1,333,309 (1.63)† |
| rF1V (0.5 μg) + MPLA (25 μg) | 68,459 (1.21) | 760,629 (1.38) |
| rF1V (0.5 μg) + Imiquimod (5 μg) | 319,494 (1.51)† | 459,479 (1.23) |
| rF1V (0.5 μg) + Imiquimod (25 μg) | 242,515 (1.17)* | 606,287 (1.17) |
| rF1V (0.5 μg) + Pam3CSK4 (5 μg) | 48,045 (1.5) | 418,918 (1.2) |
| rF1V (0.5 μg) + Pam3CSK4 (25 μg) | 25,238 (1.51)† | 801,266 (1.25) |
| rF1V (0.5 μg) + Poly (IC)LC (5 μg) | 22,006 (2.08) | 230,832 (1.67) |
| rF1V (0.5 μg) + Poly (IC)LC (25 μg) | 126,191 (1.53) | 504,766 (1.34) |
| rF1V (0.5 μg) + R848 (5 μg) | 69,644 (1.45) | 159,495 (1.31)† |
| rF1V (0.5 μg) + R848 (25 μg) | 183,792 (1.53) | 459,479 (1.14) |
a
Values represent geometric mean (Geo Mean) with geometric standard error (GSE).
b
All p- values are relative to the rF1V (0.5 Mg) control group. †p <0.05, *p <0.01, ***p <0.0001.
c
Values in parenthesis represent low (5 μg) and high (25 μg) toll-like receptor agonist amount per vaccine dose.